Functional evaluation of a corticosteroid molecule activity, dexamethasone-isonicotinate, by aerosol dosage in obstructive lung disease.
The authors experimented with a corticosteroid molecule, dexamethasone-isonicotinate, by pressurized aerosol, testing it on 15 subjects suffering from a bronchial obstructive syndrome (7 cases of asthmatic bronchitis, 6 of chronic bronchitis with pulmonary emphysema, 2 of bronchial asthma). In such patients clinical evolution, spirographic patterns, and airway resistance were studied by means of body plethysmograph before and after administration of 0.25 mg dexamethasone-isonicotinate four times a day. In four subjects daily variations of airway resistance before and after 10 days of treatment were evaluated: in three cases the resistance diminished noticeably at all times of the day after therapy. In eleven cases the functional parameters were recorded before and after 7 days therapy, and ten subjects were followed up by a monthly, check during 6 months of therapy. In both methods, the authors obtained good or very good results in more than half of the subjects and fair results in a fifth of the subjects; in the remaining patients poor results were obtained. Side-effects attributed to improper dosage were never observed.
D000336:Aerosols; D000403:Airway Resistance; D001249:Asthma / Q000188:drug therapy; D001991:Bronchitis / Q000188:drug therapy; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007539:Isonicotinic Acids; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D011656:Pulmonary Emphysema / Q000188:drug therapy; D012119:Respiration; D013147:Spirometry; D014797:Vital Capacity
D000336:Aerosols; D007539:Isonicotinic Acids; D003907:Dexamethasone